AstraZeneca’s Dato-DXd Falls Short Of Great Expectations In Lung Cancer Study

Share Price Drops 7% On News

AstraZeneca’s Dato-DXd looks to have so far failed to add a ‘clinically meaningful’ benefit over chemo in the TROPION-Lung01 study, but analysts still expect success for the investigational antibody-drug conjugate.

AstraZeneca
• Source: Shutterstock: Elzbieta Krzysztof

AstraZeneca and Daiichi Sankyo’s goal of transforming non-small cell lung cancer treatment with their antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) is looking harder to achieve after a first Phase III readout suggested results have fallen short of a best-case scenario in safety and efficacy.

The companies’ TROPION-Lung01 Phase III trial has been one of the year’s most eagerly awaited readouts, and pits the TROP2-targeted...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.